Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2018 08:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at the 2018 Bio Investor Forum

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
August 16, 2018 08:00 ET | Source: Incysus Therapeutics, Inc.

Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit

NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of...
June 08, 2018 08:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference

Symposium Title: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas” ...
May 22, 2018 08:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Moves Its Corporate Domicile to Delaware

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
May 17, 2018 08:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting

Symposium Title: “Tipping Point: Gene Therapy Entering the Market” Bruce Levine, Ph.D. to Present: “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to...
May 14, 2018 10:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy

NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of...
March 21, 2018 08:00 ET | Source: Incysus, Ltd

Incysus to Present at BioCentury Future Leaders Conference

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
March 20, 2018 08:00 ET | Source: Incysus, Ltd

Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...
February 13, 2018 16:00 ET | Source: Incysus, Ltd

Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference

NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
January 09, 2018 07:30 ET | Source: Incysus, Ltd

Incysus Submits Second Investigational New Drug Application for Gamma-Delta T Cell Immunotherapy Candidate

NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...